Conditions: Castration-Resistant Prostate Cancer
Keywords: Prostate Cancer Castration-resistant
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1199
Healthy volunteers: no

Brief summary:
This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.

Detailed description:

Arms:
arm 1: Formerly MDV3100 arm 2: None

Interventions: intervention 1: Enzalutamide intervention 2: Placebo
Intervention descriptions: intervention 1: MDV3100, 160 mg orally per day intervention 2: Placebo comparator

Protocol document: